Business Wire

Brains Bioceutical Corp. Completes a USD $31.9 Million Capital Raise with Lead Investor DSM Venturing

Share

Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ financial agent in respect to the capital raise.

“The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains' CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical industry continues to expand. Our team has worked tirelessly to position Brains as the market leader within the CBD industry. Our suite of licences has allowed Brains to scale rapidly within the industry,” Brar continued.

Pieter Wolters, Managing Director DSM Venturing, commented: “The CBD market is fast-growing, powered by increasingly strong scientific evidence that demonstrate the potential of CBD API’s in a number of therapeutic areas. Also, consumers increasingly turn to CBD’s to address health issues. Brains unparalleled expertise and manufacturing capabilities in the CBD space combined with DSM’s unique scientific and marketing capabilities in the pharmaceutical sector make this the ideal partnership to help pharmaceutical players realizing the potential of CBD’s for early stage drug development.”

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. It is also one of the rare few manufacturers in commercial production in Europe with EU-GMDP certification, producing CBD API for both human and veterinary use within a MHRA licensed facility. Brains’ CBD API—its primary offering to the market—contains 99.7% CBD and zero Tetrahydrocannabinol (THC).

Advancements made by Brains in the development of pure, natural CBD benefit the scientific and health care community on a global level. Brains phyto-cannabinoid pure CBD API has successfully been tested by the INRS Laboratory, a World Anti-Doping Agency (WADA) facility. These screening reports have confirmed that Brains’ CBD API is free of THC, pesticides and other banned substances listed by WADA. Brains is first of its kind in the industry to get such a confirmation from a WADA-accredited laboratory for the purity of its CBD and the absence of prohibitory substances. WADA has removed CBD from its banned substance list. All activities undertaken in the UK are in accordance with UK law and subject to routine, periodic inspection by UK authorities.

Brains has also launched its branded nutraceutical CBD “Brains Pure” products in top tier health and wellness retail and pharmacy chains in the UK. All Brains’ products—whether Brains-branded or white-labeled—including a partnership with a leading UK vitamin company, will bear the ‘Brains Inside®’ trademark, providing a stamp of quality assurance. Brains is also well positioned to navigate the strict Novel Foods requirements in the UK from the Food Standards Association (FSA) and in Europe by the European Food Safety Authority (EFSA) for CBD products. The Brains partnership with DSM Venturing will allow the company to take advantage of strategic partnerships that DSM has developed since their initial inception in 1902.

ABOUT BRAINS BIOCEUTICAL CORP.

Brains Bioceutical Corp. is a leader in EU-GMP-certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe. Brains’ Senior Management Team is comprised of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal Navy. Brains' wholly owned subsidiary in the UK, BSPG Laboratories, is one of only a few companies that has the commercial capability and EU-GMDP certification to produce CBD API.

About DSM Venturing

DSM Venturing is the corporate venture arm of Royal DSM – a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world’s biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.

More information can be found at www.dsm.com/venturing.

CAUTIONARY STATEMENT:

This news release contains forward looking statements or forward-looking information ("forward-looking statements") within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ricky Brar
Brains Bioceutical Corp.
Vancouver, BC, Canada
1-855-927-2476 BrainsBio.com
info@brainsbio.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Schneider Electric Moves Forward With Its Sustainability Impact Targets, Mobilizing Support From Employees, Partners and Customers30.7.2021 09:32:00 EEST | Press release

Schneider Electric, the leader in the digital transformation of energy management and automation, published today its half-year progress overview on setting up and advancing on its 2021-2025 sustainability impact targets. Schneider Electric, named as the world’s most sustainable corporation 2021 by the Corporate Knights Global 100 Index, announced the acceleration of its sustainability strategy in January, aligned to its commitments regarding climate, resources, trust, equal opportunities, generations, and local communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729006295/en/ Schneider Sustainability Impact - H1 Results (Graphic: Business Wire) Since then, the Group has successfully launched The Zero Carbon Project, its initiative to halve carbon emissions of its top supply chain partners by 2025, a call to action already joined by 91% of them. By engaging, training, and supporting the sustainable transformation

Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress30.7.2021 09:00:00 EEST | Press release

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed its fiscal year 2021 management guidance and forecast. Fiscal year 2021 remains a year of inflection with Takeda positioned for topline acceleration and continued pipeline progress, including critical regulatory submissions, potential approvals and additional new molecular entities (NMEs) advancing in pivotal studies. Costa Saroukos, Chief Financial Officer, commented: “With the Shire integration behind us and continued transformation over the last two years, we’ve pivoted towards accelerating topline growth and investing in R&D to fuel our highly innovative pipeline. Takeda’s first-quarter results demonstrate the continued strength of our 14 global brands and, with the business momentum from this strong start to our fiscal year, we remain on t

Conviva and the Trade Desk Partner to Improve Contextual Advertising for Premium Streaming Publishers29.7.2021 20:04:00 EEST | Press release

Conviva, the intelligence cloud for streaming media, and global advertising technology leader The Trade Desk, have entered a first-of-its-kind partnership to provide the streaming advertising industry the contextual content signals needed in the bidstream to improve their connected TV campaigns based on signals and effectiveness. Together, the two companies will help premium publishers supply programmatic buyers with the network, genre, rating, length and other detailed data sorely lacking in the streaming industry while still maintaining data control. Details of the partnership, product offering, participating publishers and how premium publishers can participate and benefit, will be available via a webinar in August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005953/en/ The Trade Desk + Conviva (Graphic: Business Wire) According to Conviva’s State of Streaming Advertising report, released in June 2021, only 39% o

New Harris Poll: Cybersecurity Fears May Stall COVID-19 Digital Vaccine Card Adoption in the United Kingdom, Identity Theft and Fake Cards Top List of Concerns29.7.2021 18:02:00 EEST | Press release

Anomali, the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be. A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings: 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%

QuadraGen Announces the Launch of Its Next Generation Commercial Loan Processing SaaS Platform and Edward Ho Joins As Chairman29.7.2021 17:00:00 EEST | Press release

QuadraGen announces the launch of its next generation commercial loan servicing SaaS platform to help financial institutions transform their complex loan processing capabilities. The QuadraGen Platform supports various areas of loan operations, enabling more efficient and effective processing of loan information, risk management, and decision-making. The QuadraGen SaaS platform consists of a suite of independently deployable microservices that augment existing technology, filling in gaps where processes and functions are not well executed, or replacing legacy capabilities with its next generation software. QuadraGen’s key differentiator is its team of experts, who have decades of commercial lending experience understanding and solving complex loan operation issues. Financial institutions are challenged by the size, complexity, number of participants, and speed of the loan markets. Many institutions use in-house or legacy systems that are inadequate for today’s ever-growing needs. Quadr

Comcast Announces Peacock Coming to Sky29.7.2021 16:30:00 EEST | Press release

Comcast today announced NBCUniversal and Sky will make Peacock available at no additional cost to nearly 20 million Sky customers in Europe. Beginning later this year, Peacock will make its international debut across Sky platforms, including Sky Q, NOW, and Sky Ticket, currently serving customers throughout the UK, Ireland, Germany, Italy, Austria, and Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005660/en/ “Comcast’s Xfinity has been integral to the success of our go-to-market strategy with Peacock in the U.S., and we see a similar opportunity to expand internationally with Sky,” said Jeff Shell, Chief Executive Officer, NBCUniversal. “We are excited to bring Peacock to millions of Sky customers and add incredible value to their platforms with a premium catalog of the best entertainment from across NBCUniversal that is included with their subscription. By leveraging Comcast’s Xfinity platforms in the U.

BOW Group Acquires Musart, Adding Innovative Art Marketplace to Its Offering29.7.2021 16:15:00 EEST | Press release

BOW Group today announced that it has successfully completed the acquisition of Musart.com, a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/ (Photo: Musart) “BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom